Clinical Trial Update: A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating anifrolumab for chronic and/or subacute cutaneous lupus erythematosus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Subacute Cutaneous Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Cutaneous Lupus Erythematosus | Phase 3 | Status: RECRUITING